Nasdaq ikna.

Forgot password ? RememberNov 17, 2023 · See the latest Ikena Oncology Inc stock price (IKNA:XNAS), related news, valuation, dividends and more to help you make your investing decisions. BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ...Financial Results for the Quarter Ended June 30, 2023. As of June 30, 2023, Ikena had $157.3 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...Is General American Investors Company, Inc. (NYSE:GAM) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the ...

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company forging new territory in patient-directed cancer treatment, and the Vall d’Hebron ...BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...

The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ...List with Nasdaq; Nasdaq Private Market; Nasdaq Fund Secondaries; Investor Relations Intelligence ; Nasdaq Direct Listings; Optimize Governance Practices. Board Portal …

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...List with Nasdaq; Nasdaq Private Market; Nasdaq Fund Secondaries; Investor Relations Intelligence ; Nasdaq Direct Listings; Optimize Governance Practices. Board Portal …Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...

Nov 20, 2023 · The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 20.81 when compared to last closing price of 1.49.Despite this, the company has seen a gain of 23.29% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...

(NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.Ikena Oncology. stock was originally listed at a price of $28.30 in Mar 29, 2021.

Find the latest Ikena Oncology Inc (IKNA) discussion and analysis from iHub's community of investors ... NASDAQ · Add Alert · Follow. 1. 1.71. 0.00 (0.00%). Quote ...Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community.Aug 7, 2023 · Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ... BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...

9 nov. 2023 ... Ikena Oncology, Inc (NASDAQ: IKNA) reported its quarterly financial results and presented preliminary data from the ongoing dose escalation ...Posted 8:51:03 PM. About IkenaIkena Oncology (NASDAQ: IKNA) is a clinical-stage, targeted oncology company that…See this and similar jobs on LinkedIn.IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...Oct 26, 2022 · BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

7 août 2023 ... ... Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr ...Nov 10, 2022 · BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ...

See All Market Activity. News + Insights. CLOSEIkena Oncology (NASDAQ:IKNA – Get Free Report) ‘s stock had its “outperform” rating reissued by analysts at William Blair in a research report issued to clients and investors on Thursday, RTT News reports.IKNA has been the subject of several other reports. Wedbush started coverage on Ikena Oncology in a research report on Thursday, …Financial Results for the Year Ended December 31, 2022. As of December 31, 2022, Ikena had $156.9 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient ...BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it ...BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share.Find the latest historical data for KludeIn I Acquisition Corp. Class A Common Stock (INKA) at Nasdaq.com.Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ...Nasdaq Fund Secondaries; Featured Solutions Nasdaq's IPO Process; ETF Listings; Nasdaq-100 Index Options; Derivatives AcademyNov 7, 2023 · BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in...

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...About KludeIn I Acquisition Corp. 1096 KEELER AVENUE, BERKELEY, California, 94708, United States +1 650 246-9907. KludeIn I Acquisition Corp is a blank check company.Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,656BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...IKNA. Ikena Oncology, Inc. 1.6300 +0.0300 +1.87%: TRENDING. 1. ... Both the S&P 500 and the NASDAQ indexes are back within close reach of the peak yearly values hit at the end of July, after their ...Nov 10, 2022 · BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ... Financial Results for the Quarter Ended June 30, 2023. As of June 30, 2023, Ikena had $157.3 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...Dec 1, 2023 · 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: IKNA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week. Volatility Over Time: IKNA's weekly volatility has increased from 16% to 23% over the past year. Nov 24, 2023 · Why Ikena Oncology (IKNA) Might Surprise This Earnings Season finance.yahoo.com - May 10 at 11:04 AM: Equities Analysts Offer Predictions for Ikena Oncology, Inc.'s Q1 2023 Earnings (NASDAQ:IKNA) marketbeat.com - May 8 at 1:22 AM: Ikena Oncology (NASDAQ:IKNA) Receives New Coverage from Analysts at HC Wainwright marketbeat.com - May 5 at 11:17 AM

Hollanda seçimlerinin galibi aşırı sağcı Özgürlük Partisi’ne (PVV) oy veren seçmenlerin büyük bölümünün, Geert Wilders’in Türkiye ve İslam konusundaki katı …Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ ... (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina ...Oct 18, 2022 · Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ... KludeIn I Acquisition Corp. Class A Common Stock (INKA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Instagram:https://instagram. jnk dividendnanophase technologiesbest mt4 forex brokerstarget roku Nov 30, 2023 · (NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M. Biogen Inc. (NASDAQ:BIIB) announced negative topline results from the Phase 3 STAR study of timrepigene emparvovec, an investigational gene therapy for the potential treatment of choroideremia. best brokerages for optionsis ny stock market open today BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company focused on developing novel cancer therapies targeting key ...19 oct. 2022 ... (Nasdaq: IKNA, “Ikena”), una compañía de oncología específica que forja un nuevo territorio en el tratamiento del cáncer dirigido por el ... aapl price targets The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ...Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year losses to 79%. (Simply Wall St.) Mar-17-22 07:00AM. Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update. (GlobeNewswire) +23.30%.